VivoSeq
Oncology

Transitional Cell Carcinoma

46

Pipeline Programs↗

1

Active Trials↗

25

Companies Involved↗

Transitional Cell Carcinoma is a moderately active landscape with 46 programs across 25 companies. The most active players are Oncolytics Biotech, Bayer, Rainier Therapeutics. 5 therapies are approved with 6 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

58/100

Pipeline Velocity

0/100

Mech. Concentration

18/100

Completion Rate

88/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

O

Oncolytics Biotech

1 program

Phase 1Bayer logo

Bayer

1 program

Phase 1R

Rainier Therapeutics

1 program

Phase 1Novartis logo

Novartis

4 programs

Phase 2Eli Lilly logo

Eli Lilly

2 programs

Phase 2Bristol-Myers Squibb logo

Bristol-Myers Squibb

2 programs

Phase 2

Pipeline

Programs by Phase

Preclinical5

Enfortumab Vedotin

Pfizer

Durvalumab

AstraZeneca

Pembrolizumab

Merck & Co.

Atezolizumab

Roche

Dasatinib

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 17

Sorafenib

Bayer

Sargramostim

Sanofi

REOLYSIN

Oncolytics Biotech

Suramin

Eastern Cooperative Oncology Group

B-701

Rainier Therapeutics

Phase 223

Docetaxel

Avyxa

Vinflunine

Bristol-Myers Squibb

Pemetrexed

Eagle Vision Pharmaceutical Corp.

Sapanisertib

Calithera Biosciences, Inc

Nivolumab

Bristol-Myers Squibb

Phase 36

Cisplatin

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Doxorubicin Hydrochloride

Gynecologic Oncology Group

Methotrexate

Alnylam Pharmaceuticals

Filgrastim

Eastern Cooperative Oncology Group

Gemcitabine Hydrochloride

Gynecologic Oncology Group

Approved5

Paclitaxel

Teva

Oxaliplatin

Teva

Fluorouracil

Elorac, Inc.

Mitomycin

UroGen Pharma Ltd.

Ifosfamide

Baxter Healthcare Corporation

Analysis

Modality Breakdown

79%

Small molecule

34 of 43 classified programs — the dominant modality here.

21%ALL OTHERSMonoclonal antibody512%Protein / enzyme37%Antibody–drug conjugate12%

Small molecule leads; the ring shows all 43 classified programs, each share of the total. Modality classified for 100% of 49 pipeline programs.

Analysis

Trial Status

35

clinical trials

Completed28 · 80%
Terminated3 · 9%
Unknown status2 · 6%
Withdrawn1 · 3%
Recruiting1 · 3%

Clinical Trials

Trial Activity

35 trials

A Randomized Phase II, Double-blind, Multicenter Study Evaluating the Efficacy and Safety of Autogene Cevumeran Plus Nivolumab Versus Nivolumab as Adjuvant Therapy in Patients With High-risk Muscle-invasive Urothelial Carcinoma
Recruiting·Roche logoRoche·Phase 2·NCT06534983·62 enrolled
Everolimus (RAD001) in Metastatic Transitional Cell Carcinoma of the Urothelium
Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00805129·46 enrolled
Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder
Completed·AAcrotech Biopharma Inc.·Phase 2·NCT00722553·30 enrolled
Preoperative MPDL3280A in Transitional Cell Carcinoma of the Bladder
Completed·QQueen Mary University of London·Phase 2·NCT02662309·96 enrolled
Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium
Completed·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 2·NCT00101608·150 enrolled
Phase III Trial of Vinflunine Plus Best Supportive Care vs. Best Supportive Care in Patients With Transitional Cell Carcinoma (TCC) of the Urothelial Tract
Completed·PPierre Fabre Medicament·Phase 3·NCT00315237·364 enrolled
JAVLOR Association Study in CDDP-unfit Patients With Advanced Transitional Cell Carcinoma: Gemcitabine Versus Carboplatin
Completed·PPierre Fabre Medicament·Phase 2·NCT01599013·69 enrolled
A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer
Completed·Eli Lilly logoEli Lilly·Phase 1·NCT02443324·175 enrolled
Phase I Study With Sorafenib in Addition to Vinflunine in Metastatic Transitional Cell Carcinoma of the Urothelial Tract
Completed·—·Phase 1·NCT01844947·22 enrolled
Vaccine Therapy in Treating Patients With Transitional Cell Carcinomas
Completed·LLudwig Institute for Cancer Research·Phase 1·NCT00070070·6 enrolled
Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma
Completed·National Cancer Institute (NCI)·Phase 2·NCT00072150·40 enrolled
TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced Unresectable Transitional Cell Carcinoma of the Urothelium
Completed·AAchieve Life Sciences·Phase 2·NCT00077688·44 enrolled
Phase 2 Trial of Nab-paclitaxel Plus S-1 vs Gemcitabine Plus Cisplatin as 1-line Chemotherapy of Patients With Local Advanced and/or Metastatic Transitional Cell Carcinoma of Urothelial Tract
Completed·—·Phase 2·NCT03051373·108 enrolled
Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract
Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT03430895·15 enrolled
A Phase I Trial Using Suramin to Treat Superficial Transitional Cell Carcinoma of the Bladder
Completed·National Cancer Institute (NCI)·Phase 1·NCT00001381·18 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)